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Abstract
Background: Papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC) have
always been considered different from each other; in their incidence, their cell origin and their
histopathological features.
Case presentation: This paper describes two rare cases of the simultaneous occurrence of MTC
and PTC in the thyroid gland. Case 1 is unique for different reasons: (a) the patient was affected by
both multicentric MTC and PTC; (b) a "composite thyroid carcinoma" with mixed feautures of
MTC and PTC carcinomas was found in the istmus of the gland; and (c) these tumors were
associated with diffuse lymphocytic-type thyroiditis (LT). Case 2 is notable for the long follow up:
16 years disease free.
Conclusion: There are only 16 reports in the English medical literature describing a total of 20
cases of concurrent occurrence of both PTC and MTC in the same thyroid gland. We discuss
whether the finding of another cancer in these patients was coincidental or from possible activation
of a common tumorigenic pathway for both follicular and parafollicular thyroid cells.
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Papillary thyroid carcinoma (PTC) is the most common
histological type of thyroid cancer (75–80%) [1]. It
derives from the follicular cells of the endoderm. [1]. PTC
produce thyroglobulins and thyroid hormones [1]. Med-
ullary thyroid cancer (MTC) represents only 5–8% of
cases [2]. MTC has a different embryological origin: it
derives from parafollicular cells of the ultimobranchial
body of the neural crest. MTC secrets calcitonin and other
hormonal peptides and is considered part of the amine
precursor uptake and decarboxilation system of the thy-
roid [2]. MTC may occur either as a hereditary or a nonhe-
reditary entity. Hereditary MTC can occur either alone as
familial MTC (FMTC) or as the thyroid manifestation of
multiple endocrine neoplasia type 2 syndromes [2].
Thyroid carcinoma is frequently associated with genetic
alterations. Activating point mutations of RET proto-
oncogene have been demonstrated to be causative of the
familial form of medullary thyroid cancer, both as iso-
lated FMTC and associated to MEN 2A and 2B [2].
Somatic rearrangements of RET designated as RET/PTC
(from papillary thyroid carcinoma) were identified in
papillary thyroid carcinoma before RET was recognized as
the susceptibility gene for MEN2. There are now at least at
least 15 types of RET/PTC rearrangements involving RET
and 10 different genes [1].
PTC is characterized by the presence of papillae and spe-
cific cellular changes such as epithelial cells situated on
basal membranes covering stromal fibres and thin capil-
laries, round laminated calcifications (psammoma bod-
ies), ground-glass nuclei and cytoplasmatic
pseudoinclusions [1]. MTC is composed of solid nests and
infiltrating formations of polygonal or spindle-shaped
cells, oxyphilic small cells and, sometimes, anaplastic fea-
tures. The presence of amyloidal deposits and positive
immunohistochemistry usually confirms the diagnosis of
MTC [2].
Patients with PTC have the highest 10-year relative sur-
vival (0.98). Prognosis of MTC is generally worse than
PTC (0.80) [1,2]. PTC happens to be a multicentric tumor
and tends to spread to the regional lymph nodes in the
early stage of the disease [1]. In fact, PTC is associated with
cervical lymph node metastases in 30% to 90% of patients
[1]. FMTC is often multifocal and bilateral [2]. The inci-
dence of positive lymph nodes correlates with the size of
the primary lesion at the time of diagnosis: 60% of
patients have positive lymph nodes if the MTC is larger
than 2 cm [2].
PTC and MTC have always been considered different one
from each other in terms of their incidence, their cell ori-
gin and their histopathological features. The concurrent
occurrence of both in the same patient is rare, in fact there
are only 16 reports describing a total of 20 cases in the
English language medical literature [3,4].
The aim of this report is to describe two additional cases
of this rare association. Unique pathological figures are
presented.
Case 1
A 65-year-old man was referred to our Department with a
right cervical mass on April 2005. There was no apparent
family history of endocrine disorders. The patient had not
undergo any previous external radiation therapy. Blood
pressure was normal. His serum levels of calcium, thyroid
stimulating hormone and free thyroxine were normal. The
baseline serum calcitonin level was 294 pg/ml (normal <
100 pg/ml). There were no antithyroid autoantibodies.
On physical examination a rough nodule, about 4 cm in
size, was palpated on the right side of the neck. The ultra-
sonography (US) showed a heterogeneous nodule, 4 cm
in size, in the right lobe of the thyroid and multiple nod-
ules with accompanying calcifications in the left lobe. A
single fine-needle aspiration biopsy of the right lobe nod-
ule revealed giant cells with enlarged nuclei and meta-
chromatic cytoplasmic granules. Abdominal US was
negative for adrenal nodules as well as urinary catecho-
lamines and metanephrine levels were within normal lim-
its. Total thyroidectomy plus central compartment lymph
node neck dissection were performed. Macroscopically
the right thyroid lobe measured 7 × 4 × 3.5 cm, left lobe
of the thyroid measured 4.3 × 2.5 × 2 cm. There was a right
solitary white well-circumscribed nodule of 4 cm in size,
associated with a small nodule of 0.4 in the isthmus and
a nodule (diameter 0.5 cm) with fine calcification in the
left lobe. Microscopic examination of the right nodule
confirmed medullary carcinoma of the thyroid with neo-
plastic spindle-shaped cells forming nests with pale,
abundant granular cytoplasm. Immunohistochemical
stain was positive for calcitonin and synaptophysin, and
was negative for thyroglobulin and p53. Microscopic
examination of the nodule (0.4 cm) of the isthmus
revealed co-existence of medullary and papillary carcino-
mas with follicular aspect (Figure 1). Microscopic appear-
ance of the left lobe thyroid nodule revealed papillary
carcinoma with branching papillary structure lined by
cells with empty appearing nuclei and characteristic
nuclear pseudoinclusions. Finally most of thyroid tissue
was accompanied by diffuse lymphocyte-type thyroiditis
(LT). 4 our of 19 lymph nodes of the central compartment
were positive for metastasis of medullary thyroid cancer.
TNM for PTC was pT2, N0 and for MTC was stage 3. The
patient was discharged, without complications, on the
third postoperative day. The patient underwent radioiod-
ine treatment. Analysis of tumor tissue for the RET onco-Page 2 of 5
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serum calcitonin and TG levels were within normal range.
Case 2
In May 1990 a 34-year-old woman, with no relevant past
or family history, underwent a surgical biopsy of enlarged
lymph nodes on the left side of the neck. Histological
result was compatible with metastasis of carcinoma, pos-
sibly originated from her thyroid. Subsequent US of the
gland showed an ipo-echoic irregular nodule in the left
lobe, with some micro calcifications, of 2.7 × 1.9 cm in
size and another little nodule with similar features near
the isthmus. A small ipo-echoic nodule of 1 cm in size,
probably a lymph node, was described on the left side of
trachea. No pathological features were noted in the right
lobe. The scintigraphy of the thyroid showed a cold area
corresponding to the nodule described on the left lobe at
US. Her serum level of thyroid hormones was normal,
while calcitonin was >1000 pg/ml and CEA was 661 pg/
ml. Total thyroidectomy and left neck dissection were per-
formed. Histological result showed a solid white nodule
in the thyroid lobe (2 cm in size) consistent with medul-
lary thyroid carcinoma with solid pattern, nests of spin-
dle-shaped cells and amyloidal deposits, positive reaction
for CGRP and calcitonin (Figure 2). Another grey-white
nodule with calcifications (0.3 cm in size) was described
in the right lobe, consistent with papillary thyroid carci-
noma, with neoplastic cells showing overlapping clear
nuclei and abundant eosinophilic cytoplasm (tall cell var-
iant) (Figure 3) (tumor categories were pT2, N+). The
patient was discharged without complications and surgi-
cal treatment was followed by irradiation of the neck (46
GY of total dose). During follow up calcitonin levels were
between 300 and 200 pg/ml. A new scintigraphy with 131I
and MIBG was performed on September 1990: it demon-
strated a residual neoplasm in the cervical area. Another
surgical excision biopsy was executed and 5 lymph nodes
were removed. Histological result showed metastasis of
papillary carcinoma. No more therapy was carried out.
The patient is still alive, free from illness (now 16 years
disease free).
Papillary thyroid carcinoma: the neoplastic cells show over-lapping clear nuclei and abundant sinophilic cytoplasm (tall cell v iant) (H&E 400×)Figure 3
Papillary thyroid carcinoma: the neoplastic cells show over-
lapping clear nuclei and abundant eosinophilic cytoplasm (tall 
cell variant) (H&E 400×).
Coexistence of (right) medullary and (left) papillary carci-noma with follicular aspect (H&E, 100×)Figure 1
Coexistence of (right) medullary and (left) papillary carci-
noma with follicular aspect (H&E, 100×).
Positive immunostaining reaction for CGRP and calcitonin (DAB-Hae atoxylin 400×)Figure 2
Positive immunostaining reaction for CGRP and calcitonin 
(DAB-Haematoxylin 400×).Page 3 of 5
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MTC is a rare and aggressive type of thyroid cancer with
several distinctive features that distinguish its manage-
ment from PTC. Since MTC was first recognised as a dis-
tinct tumour in 1959, it became clear that MTC is more
difficult to cure than PTC and has higher rates of recur-
rence and mortality [1,2]. In addition, unlike PTC cancer,
there is no known effective systemic therapy for MTC [2].
These cases are peculiar for the unique pathological fea-
tures. In particular, case 1 is extremely rare and of high
interest for different reasons: (a) the patient was affected
by both multicentric MTC and PTC (this is the first report
of a multifocal occurrence of different histological types of
thyroid carcinomas in the same gland); (b) in addition a
composite thyroid carcinoma with mixed features of MTC
and PTC carcinomas was found in the isthmus of the
gland; (c) the association of these tumours with diffuse
lymphocyte-type thyroiditis. Case 2 is notable for the long
follow up (16 years disease free).
The question is whether the finding of another thyroid
cancer in these patients was coincidental or from possible
activation of a common tumorigenic pathway for both
follicular and parafollicular thyroid cells. It is apparent
that in the last decade, carcinoma of the thyroid is becom-
ing increasingly prevalent. In fact, the incidence of thyroid
carcinoma in Europe has increased during the period
1978–1997, by 3% per year, largely due to an increase rate
of PTC [1]. In Italy, PTC is the most frequent thyroid can-
cer and shows a significant increase of incidence rates [1].
The pathogenesis of thyroid malignancy is unknown, but
an underlying common genetic drive has been hypothe-
sized. The process of thyroid oncogenesis is conceived to
be a series of events induced by genetic and environmen-
tal factors which alter thyroid cell division and growth
control. These factors can be considered as initiators and
promoters [5]. The first class of factors induce incipient
tumor genesis while the second augments TSH secretion
and radically increases tumor growth [5]. Normally silent,
intracellular proto-oncogenes can become activated by
chromosomal translocations, deletions or mutations and
can transform normal thyroid cell into a condition of
uncontrolled division and growth [5]. The most signifi-
cant known cause of thyroid carcinomas is exposure to
external or internal ionizing radiation [5]. Several early
events have been implicated in the neoplastic transforma-
tion of thyrocytes, and recent reports have described the
involvement of specific genetic alterations in different
types of thyroid neoplasms [5]. Recent studies revealed
that the RET proto-oncogene is involved in the oncogene-
sis of MTC and PTC by activation of its tyrosine kinase
either by point mutation or rearrangement [5]. Activating
germ-line point mutations in the RET receptor are respon-
sible for multiple endocrine neoplasia type 2-associated
MTC, whereas somatic RET rearrangements are prevalent
in PTC [5].
In the English language medical literature there are 12
reports describing cases of mixed medullary-papillary car-
cinomas [3,4]. Apel first proposed the term of "composite
thyroid carcinoma" [6]. This can be explained if we con-
sider the theory of a common stem cell, proposed by Ljun-
berg [7]. According to this theory, the ultimobranchial
body is the most likely source of this putative common
stem cell because the nests of these cells in the thyroid
gland show immunoreactivity for both thyroglobulin and
calcitonin, suggesting that the ultimobranchial body have
contributed to both the parafollicular and follicular cells
[6,7]. In contrast to this theory, Volante proposed that the
components of the two carcinomas are not derived from a
single progenitor cell, because they observed different pat-
terns of RET proto-oncogene mutation, loss of heterozy-
gosis and X-chromosomal inactivation in a lot of these
tumours [8]. Furthermore, it has been supposed that
unknown factors are necessary to be present for the stim-
ulation of follicular cells, as well as the detection of these
substances in the MTC of mixed medullary and follicular
carcinomas and their absence in classical medullary thy-
roid cells [8]. Recently Rossi reported three cases of MTC/
PTC collision tumour in which two mutations, in the RET
and BRAF genes, were identified, thus documenting the
different genetic origin of these two coexisting carcinomas
[9].
Finally, PTC is often accompanied by LT a phenomenon
that may give rise to analyses both to pathogenetic mech-
anisms and to prognostic implications [10]. Coexisting LT
has been shown to be associate with lower pT stages [10].
Authors have shown that apart from age (45 years or
more), vascular invasion, and lymph node metastases, the
absence of LT represents an independent prognostic indi-
cator both for relapse-free and overall survival [10].
Recently, Tamini reported that the prevalence of lym-
phocytic infiltrate is significantly higher in patients with
papillary carcinoma (58%) than in patients with follicular
carcinoma (20%) or follicular adenoma (14%): the possi-
bility that an immunologic mechanism involved in the
pathogenesis of papillary carcinoma stimulates lym-
phocytic infiltration in the thyroid tissue through an
autoimmune mechanism was suggested [10]. There are no
data in literature of the association of MTC and LT.
Competing interests
The author(s) declare that they have no competing inter-
ests.Page 4 of 5
(page number not for citation purposes)
Journal of Medical Case Reports 2007, 1:133 http://www.jmedicalcasereports.com/content/1/1/133Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Authors' contributions
GD: acquisition of data, PC, LB: study conception and
design, VB, FR, RD: analysis and interpretation of data,
MLT, LB: drafting of manuscript, CC, RD, LB: Critical revi-
sion and supervision
Acknowledgements
Written informed consent was obtained from both patients for publication 
of this case report.
References
1. Rosai J: Handling of thyroid follicular patterned lesions.  Endocr
Pathol 2005, 16:279-83.
2. Ball DW: Medullary thyroid cancer: therapeutic targets and
molecular markers.  Curr Opin Oncol 2007, 19:18-23.
3. Merchant FH, Hirschowits SL, Cohan P: Simultaneous occurrence
of medullary and papillary carcinoma of the thyroid gland
identified by fine needle aspiration: a case report.  Acta Cytol
2002, 46:762-6.
4. Mazziotti G, Rotondi M, Manganella G: Medullary thyroid cancer,
papillary thyroid microcarcinoma and Graves disease: an
unusual clinical coexistance.  J Endocrinol Invest 2001, 24:892-6.
5. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlum-
berger M, Suarez HG: High prevalence of activating ret proto-
oncogene rearrangements, in thyroid tumors from patients
who had received external radiation.  Oncogene 1997,
15:1263-73.
6. Apel RL, Alpert L, Rizzo A: A metastasizing composite carci-
noma of the thyroid with distinct medullary and papillary
components.  Arch Pathol Lab Med 1994, 118:1143-7.
7. Ljungberg O, Ericsson UB, Bondeson L, Thorell J: A compound fol-
licular-parafollicular cell carcinoma of the thyroid: a new
tumor entity?  Cancer 1983, 52:1053-61.
8. Volante M, Papotti M, Roth J, Saremaslani P, Speel EJ, Lloyd RV, Car-
ney JA, Heitz PU, Bussolati G, Komminoth P: Mixed medullary-fol-
licular thyroid carcinoma. Molecular evidence for a dual
origin of tumor components.  Am J Pathol 1999, 155:1499-509.
9. Rossi S, Fugazzola L, De Pasquale L, Braidotti P, Cirello V, Beck-Pec-
coz P, Bosari S, Bastagli A: Medullary and papillary carcinoma of
the thyroid gland occurring as a collision tumour: report of
three cases with molecular analysis and review of the litera-
ture.  Endocr Relat Cancer 2005, 12:281-9.
10. Tamimi DM: The association between chronic lymphocytic
thyroiditis and thyroid tumors.  Int J Surg Pathol 2002, 10:141-6.Page 5 of 5
(page number not for citation purposes)
